Atlas Trials

Lumacaftor/Ivacaftor Combination Therapy in Subjects With CF Who Have an A455E CFTR Mutation

Clinical trial NCT03061331 · COMPLETED

Trial details

NCT number
NCT03061331
Sponsor
Vertex Pharmaceuticals Incorporated
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Cystic Fibrosis
Start date
2017-01-31
Primary completion
2017-09-06
Enrollment
20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.